Ultimately, the removal of c-Abl from myofibroblasts was found to be beneficial in established kidney fibrosis, suggesting that targeting c-Abl could be a potent therapeutic strategy for mitigating kidney fibrosis and decelerating the progression of CKD. Here, ABL1 is linked to chronic kidney disease.